Lexeo Therapeutics (LXEO) Non-Current Assets (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Non-Current Assets data on file, last reported at $49.5 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 142.43% year-over-year to $49.5 million; the trailing twelve-month figure through Mar 2026 stood at $181.8 million (up 157.93% YoY), and the FY2025 full-year result was $80.3 million, up 285.65% from the prior year.
• Non-Current Assets retreated to $49.5 million in Q1 2026, from $80.3 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $80.3 million in Q4 2025 to a low of $14.4 million in Q3 2024.
• A 5-year average of $26.3 million and a median of $16.5 million in 2022 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets decreased 9.1% in 2024 and surged 285.65% in 2025, its largest moves.
• Tracing LXEO's Non-Current Assets over 5 years: stood at $17.0 million in 2022, then declined by 8.9% to $15.5 million in 2023, then surged by 34.22% to $20.8 million in 2024, then surged by 285.65% to $80.3 million in 2025, then sank by 38.36% to $49.5 million in 2026.
• Business Quant data shows LXEO's Non-Current Assets at $49.5 million in Q1 2026, $80.3 million in Q4 2025, and $16.1 million in Q3 2025.